News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
274,281 Results
Type
Article (14261)
Company Profile (105)
Press Release (259907)
Multimedia
Podcasts (65)
Webinars (13)
Section
Business (88374)
Career Advice (465)
Deals (15417)
Drug Delivery (73)
Drug Development (36777)
Employer Resources (50)
FDA (6392)
Job Trends (6242)
News (150920)
Policy (14160)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (444)
Accelerated approval (14)
Adcomms (8)
Allergies (67)
Alliances (23348)
ALS (56)
Alzheimer's disease (478)
Antibody-drug conjugate (ADC) (100)
Approvals (6583)
Artificial intelligence (201)
Autoimmune disease (39)
Automation (12)
Bankruptcy (150)
Best Places to Work (4377)
BIOSECURE Act (9)
Biosimilars (118)
Biotechnology (40)
Bladder cancer (38)
Brain cancer (30)
Breast cancer (171)
Cancer (1318)
Cardiovascular disease (151)
Career advice (418)
Career pathing (13)
CAR-T (49)
CDC (6)
Cell therapy (150)
Cervical cancer (9)
Clinical research (32074)
Collaboration (725)
Compensation (325)
Complete response letters (33)
COVID-19 (778)
CRISPR (43)
C-suite (433)
Cystic fibrosis (58)
Data (1821)
Denatured (18)
Depression (45)
Diabetes (126)
Diagnostics (1382)
Digital health (8)
Diversity (2)
Diversity, equity & inclusion (14)
Drug discovery (113)
Drug pricing (114)
Drug shortages (12)
Duchenne muscular dystrophy (80)
Earnings (33519)
Editorial (21)
Employer branding (4)
Employer resources (45)
Events (39057)
Executive appointments (529)
FDA (7490)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (429)
Gene editing (70)
Generative AI (18)
Gene therapy (165)
GLP-1 (439)
Government (1404)
Grass and pollen (4)
Guidances (164)
Healthcare (3582)
HIV (11)
Huntington's disease (9)
IgA nephropathy (37)
Immunology and inflammation (68)
Immuno-oncology (14)
Indications (53)
Infectious disease (842)
Inflammatory bowel disease (73)
Inflation Reduction Act (7)
Influenza (24)
Intellectual property (113)
Interviews (60)
IPO (5930)
IRA (33)
Job creations (2058)
Job search strategy (374)
JPM (28)
Kidney cancer (9)
Labor market (28)
Layoffs (205)
Leadership (8)
Legal (3452)
Liver cancer (22)
Longevity (8)
Lung cancer (185)
Lymphoma (123)
Machine learning (13)
Management (17)
Manufacturing (412)
MASH (67)
Medical device (1306)
Medtech (1313)
Mergers & acquisitions (9907)
Metabolic disorders (434)
Multiple sclerosis (46)
NASH (14)
Neurodegenerative disease (82)
Neuropsychiatric disorders (37)
Neuroscience (887)
Neurotech (1)
NextGen: Class of 2026 (1588)
Non-profit (600)
Now hiring (17)
Obesity (227)
Opinion (141)
Ovarian cancer (39)
Pain (109)
Pancreatic cancer (51)
Parkinson's disease (80)
Partnered (11)
Patents (221)
Patient recruitment (116)
Peanut (12)
People (29757)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase 1 (8310)
Phase 2 (13550)
Phase 3 (12231)
Pipeline (1906)
Policy (135)
Postmarket research (1402)
Preclinical (3344)
Press Release (25)
Prostate cancer (84)
Psychedelics (16)
Radiopharmaceuticals (135)
Rare diseases (350)
Real estate (2661)
Recruiting (18)
Regulatory (10983)
Reports (15)
Research institute (575)
Resumes & cover letters (55)
Rett syndrome (5)
RNA editing (6)
RSV (20)
Schizophrenia (69)
Series A (80)
Series B (49)
Service/supplier (2)
Sickle cell disease (46)
Special edition (10)
Spinal muscular atrophy (81)
Sponsored (9)
Startups (1645)
State (2)
Stomach cancer (5)
Supply chain (49)
Tariffs (68)
The Weekly (45)
Vaccines (231)
Venture capital (32)
Weight loss (140)
Women's health (27)
Worklife (4)
Date
Last 7 days (177)
Last 30 days (676)
Last 365 days (10411)
2026 (952)
2025 (10719)
2024 (12504)
2023 (14252)
2022 (19561)
2021 (20074)
2020 (19043)
2019 (14909)
2018 (11734)
2017 (13901)
2016 (13150)
2015 (15490)
2014 (12441)
2013 (10653)
2012 (11472)
2011 (11998)
2010 (10939)
Location
Africa (318)
Alabama (19)
Alaska (1)
Arizona (77)
Arkansas (3)
Asia (20892)
Australia (2687)
California (3179)
Canada (1481)
China (550)
Colorado (143)
Connecticut (129)
Delaware (123)
Europe (40880)
Florida (601)
Georgia (63)
Hawaii (1)
Idaho (10)
Illinois (348)
India (44)
Indiana (240)
Iowa (2)
Japan (246)
Kansas (77)
Kentucky (20)
Louisiana (4)
Maine (2)
Maryland (421)
Massachusetts (2587)
Michigan (46)
Minnesota (165)
Mississippi (1)
Missouri (33)
Montana (8)
Nebraska (7)
Nevada (16)
New Hampshire (8)
New Jersey (1396)
New Mexico (7)
New York (906)
North Carolina (619)
North Dakota (2)
Northern California (1447)
Ohio (80)
Oklahoma (5)
Oregon (18)
Pennsylvania (716)
Puerto Rico (12)
Rhode Island (17)
South America (508)
South Carolina (10)
Southern California (1389)
Tennessee (53)
Texas (458)
United States (12676)
Utah (59)
Virginia (160)
Washington D.C. (42)
Washington State (223)
West Virginia (1)
Wisconsin (37)
Wyoming (1)
274,281 Results for "adarx pharmaceuticals inc.rss".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
ADARx Pharmaceuticals Appoints Donald Fong, M.D., as Chief Medical Officer
February 5, 2026
·
3 min read
Press Releases
ADARx Pharmaceuticals Appoints Mary Tagliaferri, M.D., to its Board of Directors
December 3, 2025
·
3 min read
Drug discovery
AbbVie Dives Further Into siRNA With $335M Upfront in ADARx Deal
The ADARx Pharmaceuticals partnership, which could be worth “several billion dollars” in the end, adds to AbbVie’s existing work in the space after the $1.4 billion acquisition of Aliada Therapeutics in October 2024.
May 14, 2025
·
2 min read
·
Annalee Armstrong
Press Releases
ADARx Pharmaceuticals Announces Clinical Data Presentation at the American Society of Nephrology (ASN) Kidney Week 2025
October 21, 2025
·
2 min read
Press Releases
ADARx Pharmaceuticals Announces Positive Interim Phase 1 Clinical Data for its Novel siRNA Targeting Complement Factor B (CFB)
November 10, 2025
·
4 min read
Press Releases
ADARx Pharmaceuticals Appoints Industry Veteran, Laura Shawver, Ph.D., as Board Chair
September 18, 2025
·
2 min read
Press Releases
ADARx Pharmaceuticals to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
September 5, 2025
·
1 min read
Press Releases
ADARx Pharmaceuticals Announces First Patient Dosed in Phase 3 STOP-HAE Clinical Trial and Orphan Drug Designation for ADX-324, a Long-Acting siRNA in Development for the Prophylactic Treatment of Hereditary Angioedema (HAE)
October 23, 2025
·
3 min read
Business
ADARx Pharmaceuticals Appoints Dr. Chris Storgard as Chief Medical Officer
ADARx Pharmaceuticals, Inc. today announced the appointment of Chris Storgard, M.D., as Chief Medical Officer (CMO).
April 2, 2024
·
3 min read
Press Releases
AbbVie and ADARx Pharmaceuticals Announce Collaboration and License Option Agreement to Develop Next-Generation siRNA Therapies Across Multiple Therapeutic Areas
May 14, 2025
·
5 min read
1 of 27,429
Next
